JNJ 42721458

Drug Profile

JNJ 42721458

Alternative Names: JNJ-42721458

Latest Information Update: 21 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen Research & Development
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Unspecified

Most Recent Events

  • 30 Apr 2013 Phase-I clinical trials in Undefined indication in Belgium (SC)
  • 23 Apr 2013 Preclinical trials in Undefined indication in Belgium (SC)
  • 23 Apr 2013 Janssen plans a phase I trial in Healthy volunteers in Belgium (NCT01840501)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top